

Episode 77
Oct 25, 2023
Biotech analysts Jacob Plieth and Madeleine Armstrong, along with Nuvalent CEO Jim Porter, discuss Merck and Daichii's co-development deal, Nuvalent's $300M raise, and recent industry data. They also touch on the recent ESMO data breach, PTC Therapeutics' agreement with Royalty Pharma, and Revolution Medicines' KRAS data, among other topics.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 3min
Two Interesting Deals in the Biotech Industry
03:12 • 19min
Progress and Challenges in Small-School Lung Cancer Treatment
22:08 • 2min
New Valent's Success and Future Plans
24:25 • 20min
Struggle of Innate Immune Platforms in Autoimmune Treatment and the Potential of Car T Therapeutics
44:22 • 6min
Updates from ABBAVX and Pfizer
50:06 • 6min
Focus on K-RAS at Esmo and Upcoming Events
55:58 • 2min